Skip to content
Home
Company
About Us
Leadership
Management
Board of Directors
Scientific
Advisory Board
Science
Evorpacept
Publications
Pipeline
Clinical Trials
Expanded
Access Policy
Careers
Current Jobs
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact
ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies
Post navigation
Previous:
Targeting the Myeloid Checkpoint Receptor SIRPα Potentiates Innate and Adaptive Immune Responses to Promote Anti‑Tumor Activity
Next:
ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma; ASPEN-01
